Quantum Biopharma (QNTM) News Today $9.24 +1.43 (+18.31%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.75 +0.51 (+5.54%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNTM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Quantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging StudyMay 20 at 4:34 PM | finance.yahoo.comQuantum BioPharma shares climb as multiple sclerosis imaging study advances (QNTM)May 18, 2026 | msn.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging StudyMay 18, 2026 | markets.businessinsider.comQuantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General HospitalMay 18, 2026 | globenewswire.comQuantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026May 7, 2026 | globenewswire.comQuantum BioPharma (QNTM) price target increased by 10.88% to 36.72April 28, 2026 | msn.comQuantum BioPharma Provides Corporate UpdateApril 27, 2026 | globenewswire.comQuantum BioPharma Ltd.April 24, 2026 | barrons.comQuantum BioPharma’s Unbuzzd Licensee Names New CEO to Drive U.S. Rollout of Clinically Backed Hangover BeverageApril 24, 2026 | theglobeandmail.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and ...April 24, 2026 | markets.businessinsider.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism AccelerantApril 22, 2026 | globenewswire.comQuantum Biopharma Ltd. Subordinate Voting Shares Class BApril 13, 2026 | edition.cnn.comQuantum BioPharma Cleared to Proceed With $700 Million Market Manipulation Lawsuit After Motion to Dismiss Largely DeniedApril 4, 2026 | theglobeandmail.comQuantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets ...April 2, 2026 | markets.businessinsider.comQuantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple SclerosisApril 1, 2026 | globenewswire.comWhy did QNTM stock pop in pre-market today?March 30, 2026 | msn.comQuantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple SclerosisMarch 30, 2026 | globenewswire.comQuantum Biopharma Provides Corporate UpdateMarch 27, 2026 | globenewswire.comQuantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' StatusMarch 27, 2026 | globenewswire.comQuantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With UnbuzzdMarch 23, 2026 | globenewswire.comQuantum Biopharma Announces Closing of Initial Tranche of Private Placement OfferingMarch 20, 2026 | globenewswire.comQuantum BioPharma Eases Debenture Terms After Share Price DropMarch 13, 2026 | theglobeandmail.comQuantum BioPharma Provides Corporate UpdateMarch 11, 2026 | globenewswire.comQuantum BioPharma Provides Corporate UpdateMarch 10, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTMFebruary 19, 2026 | prnewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmFebruary 19, 2026 | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. InvestorsFebruary 17, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTMFebruary 17, 2026 | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Quantum Corporation InvestorsFebruary 17, 2026 | globenewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTMFebruary 12, 2026 | prnewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmFebruary 12, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmFebruary 9, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmFebruary 5, 2026 | globenewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTMFebruary 3, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmFebruary 2, 2026 | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. InvestorsFebruary 2, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJanuary 29, 2026 | globenewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTMJanuary 29, 2026 | prnewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTMJanuary 27, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJanuary 26, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJanuary 22, 2026 | globenewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTMJanuary 22, 2026 | prnewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTMJanuary 20, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJanuary 19, 2026 | globenewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTMJanuary 15, 2026 | prnewswire.comCONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTMJanuary 13, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJanuary 12, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJanuary 8, 2026 | globenewswire.comKaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026January 7, 2026 | theglobeandmail.comKaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action LawsuitJanuary 3, 2026 | theglobeandmail.com Get Quantum Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNTM Media Mentions By Week QNTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNTM News Sentiment▼0.150.45▲Average Medical News Sentiment QNTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNTM Articles This Week▼43▲QNTM Articles Average Week Get the Latest News and Ratings for QNTM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Quantum Biopharma and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Oncolytics Biotech News Aardvark Therapeutics News Promis Neurosciences News Upexi News Anixa Biosciences News Biomea Fusion News ImmuCell News Clene News Cue Biopharma News Atara Biotherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNTM) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
